Livia Stanger and Colleagues Link CS014 to in Vivo Thrombosis
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
CS014, a novel HDAC inhibitor, prevents blood clots as effectively as valproic acid but without hepatotoxic metabolites, offering safer antithrombotic therapy without increasing bleeding risk.”
Read the full article here.
Article: Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Authors: Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, Nicholas Oakes, Jonas Faijerson Säljö, Björn Dahlöf, Joan Beckman, Michael Holinstat
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD
-
Sep 29, 2026, 10:49Alison Davey: The Vital Role of Community Support in Bleeding Disorders
-
Sep 29, 2026, 10:36Abdul Muqtadir Abbasi: 5 Questions to Ask When the CBC Is Abnormal
-
Sep 29, 2026, 10:28Manu Morales Sánchez: DOACs in Intermediate Risk Atrial Fibrillation
-
Sep 29, 2026, 09:59William Sauer: Ablation in Patients With LAAO Devices
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet